Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Intellia Therapeutics (NTLA) Reports Q1 Loss of $0.49/Share
May 2, 2019 7:43 AM EDTIntellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.49), versus ($0.51) reported last year. Revenue for the quarter came in at $10.43 million, versus $7.47 million reported last year.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
... More